The Pharma Letter M&A roundup - May 2022

6 June 2022

The biggest pharmaceutical M&A deal of 2022 so far was announced in May, along with five other notable acquisitions.

Perhaps not surprisingly, given the US pharma giant's huge pile of cash earned from its COVID-19 vaccine and treatment sales, the company behind the huge buyout was Pfizer (NYSE), as it snapped up Biohaven Pharmaceutical for $11.6 billion to add to its migraine drugs portfolio.

UK-based GSK (NYSE: GSK) was responsible for the month's other large acquisition by a pharma major as it snapped up vaccines technology company Affinivax. The other three deals announced were more modest but interesting nonetheless, with the table below showing more details on each buyout and the reasons behind it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK